What the FDA labels say about taking them together
Ritonavir and simvastatin
Ritonavir's FDA label of July 23, 2026 names simvastatin in its contraindications section, and simvastatin's label names ritonavir too. The simvastatin label: “Simvastatin is a substrate of CYP3A4. Concomitant use of strong CYP3A4 inhibitors with ZOCOR increases simvastatin exposure and increases the risk of myopathy and rhabdomyolysis, particularly with higher ZOCOR dosages.”
Check it at the source: the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.); the simvastatin FDA label on DailyMed (effective March 28, 2025, Organon LLC).
What does the ritonavir label say about simvastatin?
Ritonavir label, contraindicationsNORVIR is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )]. ○ Alpha 1- Adrenoreceptor Antagonist: alfuzosin ○ Antianginal: ranolazine ○ Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine ○ Antifungal: voriconazole ○ Anti-gout: colchicine ○ Antipsychotics: lurasidone, pimozide ○ Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine ○ GI Motility Agent: cisapride ○ HMG-CoA Reductase Inhibitors: lovastatin, simvastatin ○ Microsomal triglyceride transfer …
Ritonavir label, drug interactionsConcomitant Drug Class/Drug Name: Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide; Effect on Concentration of Ritonavir or Concomitant Drug: ↑ lovastatin ↑ simvastatin ↑ atorvastatin ↑ rosuvastatin ↑ lomitapide; Clinical Comment: Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications () ]. …
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
What does the simvastatin label say about ritonavir?
Simvastatin label, drug interactionsStrong CYP3A4 inhibitors Clinical Impact: Simvastatin is a substrate of CYP3A4. Concomitant use of strong CYP3A4 inhibitors with ZOCOR increases simvastatin exposure and increases the risk of myopathy and rhabdomyolysis, particularly with higher ZOCOR dosages. … antibiotics (e.g., erythromycin and clarithromycin), select HIV protease inhibitors (e.g., nelfinavir, ritonavir, and darunavir/ritonavir), select HCV protease inhibitors (e.g., boceprevir and telaprevir), cobicistat-containing products, and nefazodone.
Source: FDA drug label (ZOCOR), Organon LLC, effective March 28, 2025 (SPL set 8f55d5de-5a4f-4a39-8c84-c53976dd6af9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Which combination products and biosimilars carry the same label text?
Their labels quote the same sentences for their ingredient; each has its own page with its own label dates.
Both medicines on the record
| Ritonavir | Simvastatin | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, High cholesterol, High triglycerides |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.607 per tablet 100 mg tablet | $0.0321 per tablet 20 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once